Nigrostriatal Pathway Dopaminergic Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Nigrostriatal pathway dopaminergic neurons are a critical subset of substantia nigra pars compacta (SNc) neurons that project to the dorsal striatum (caudate nucleus and putamen). These neurons form the nigrostriatal pathway, which is essential for motor control and is devastated in Parkinson's disease.
- Substantia nigra pars compacta (SNc)
- Ventral tier neurons preferentially
- Calbindin-negative subpopulation
- High neuromelanin content
- Dorsal striatum (caudate/putamen) primary target
- Topographic organization
- Dense innervation pattern
- Synaptic specializations
- Striatal medium spiny neuron targeting
- Direct and indirect pathway modulation
- Cortical loop involvement
- Thalamic feedback
- Tyrosine hydroxylase (TH)
- Aromatic L-amino acid decarboxylase (AADC)
- Vesicular monoamine transporter 2 (VMAT2)
- Dopamine transporter (DAT)
- Nurr1 (NR4A2)
- Pitx3
- Lmx1a/b
- Otx2
¶ Calcium Handling
- Cav1.3 calcium channels
- Calbindin expression (variable)
- Calmodulin interactions
- ER calcium dynamics
- Lewy body formation
- Alpha-synuclein aggregation
- Mitochondrial complex I deficiency
- Oxidative stress
- High metabolic demand
- Calcium dysregulation
- Autophagy impairment
- Neuroinflammation
- Motor symptoms correlation
- Striatal dopamine depletion
- FD-PET imaging markers
- Treatment response prediction
- iPSC-derived DA neurons
- Organoid models
- Microfluidic devices
- 3D culture systems
- 6-OHDA lesioned rats
- MPTP-treated primates
- Alpha-synuclein transgenic mice
- LRRK2 mutant models
- L-DOPA replacement
- Dopamine agonists
- MAO-B inhibitors
- COMT inhibitors
- Deep brain stimulation
- Lesion procedures
- Gene therapy targets
- Cell transplantation
- Neuroprotective compounds
- Alpha-synuclein targeting
- Mitochondrial protectants
- Cell replacement therapy
The study of Nigrostriatal Pathway Dopaminergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Jellinger KA. Neuropathology of Parkinson's disease. J Neural Transm Suppl. 2003;(65):145-151.
- Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain: I. Nigrosomes and the nigral matrix. Brain. 1999;122(Pt 8):1437-1448.
- Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912.
- Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 1996;55(3):259-272.
- Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially vulnerable in Parkinson's disease. Nature. 1988;334(6179):345-348.
- Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons. J Neural Transm Suppl. 2011;(72):21-30.
- Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010;67(6):715-725.
- Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol. 2009;201:1-119.